Cynthia A. Behling

Cynthia A. Behling

Auto-generated profile, based on publicly available information

Cynthia A. Behling

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics University of California San Diego School of Medicine La Jolla California USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Hepatology
Verified
Journal Article
Closed access
SXStavra A. Xanthakos
Stavra A. Xanthakos
Samar IbrahimSamar Ibrahim
Samar Ibrahim
KAKathryn Adams
Kathryn Adams
RKRohit Kohli
Rohit Kohli
PSPushpa Sathya
Pushpa Sathya
JSJeffrey B. Schwimmer
Jeffrey B. Schwimmer
Given the high prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in children and its distinct epidemiological, clinical, and histopathological differences from adult disease, the American Association for the Study of Liver Diseases (AASLD) commissioned this pediatric-focused evidence-based practice statement. A multidisciplinary writing group—encompassing expertise in pediatric hepatology, gastroenterology, endocrinology, and liver pathology—conducted a comprehensive PubMed literature search for studies published through March 6, 2024, involving pediatric participants (ages 0–18 y) with NAFLD or MASLD. The review addressed epidemiology, pathophysiology, natural history, screening, diagnosis, treatment, comorbidity management, outcome monitoring, and transition of care. Using the highest available level of evidence—randomized controlled trials, large observational cohort studies, systematic reviews, and meta-analyses—30 evidence-guided practice statements were developed. Where high-quality evidence was lacking, expert consensus was employed, and critical knowledge gaps were identified to inform future research priorities. This document highlights key concepts relevant to pediatric MASLD, especially regarding diagnostic criteria, noninvasive assessment tools, and therapeutic approaches. It also discusses the implications of the 2023 nomenclature revision, which emphasizes evaluating both hepatic steatosis and cardiometabolic risk factors. With increasing recognition of MASLD’s cardiometabolic burden and long-term health consequences, this practice statement provides a structured framework to advance clinical care and research in pediatric MASLD.

24 September 2025 in Journal of Hepatology
Verified
Journal Article
Closed access
EVEduardo Vilar-Gomez
Eduardo Vilar-Gomez
KYKatherine P. Yates
Katherine P. Yates
DKDavid E. Kleiner
David E. Kleiner
CBCynthia Behling
Cynthia Behling
OCOscar W. Cummings
Oscar W. Cummings
NCNaga Chalasani
Naga Chalasani

1 February 2023 in Hepatology Communications
Verified
Journal Article
Closed access
RGRyan M. Gill
Ryan M. Gill
DADaniela Allende
Daniela Allende
PBPatricia H. Belt
Patricia H. Belt
CBCynthia A. Behling
Cynthia A. Behling
OCOscar W. Cummings
Oscar W. Cummings
FCfor the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
Background and Aims: The NAFLD activity score was developed to measure histologic changes in NAFLD during therapeutic trials. Hepatocyte ballooning (HB) is the most specific feature in steatohepatitis diagnosis, yet the impact of variations in HB has not been incorporated. Approach and Results: Liver biopsies from patients enrolled in the NASH Clinical Research Network with an initial diagnosis of NASH or NAFL (n=1688) were evaluated to distinguish classic hepatocyte ballooning (cHB) from smaller, nonclassic hepatocyte ballooning (nHB), and also to designate severe ballooning and assign an extended hepatocyte ballooning (eB) score [0 points, no ballooning (NB); 1 point, few or many nHB; 2 points, few cHB; 3 points, many cHB; 4 points, severe cHB] to the biopsy assessment. The eB score was reproducible among NASH CRN liver pathologists (weighted kappa 0.76) and was significantly associated with older age (mean 52.1 y, cHB; 48.5 y, nHB, p<0.001), gender (72.3% female, cHB; 54.5% female, nHB, p<0.001), diabetes (49.8% diabetes, cHB; 28.2% diabetes, nHB, p<0.001), metabolic syndrome (68.5% metabolic syndrome, nHB; 50.2% metabolic syndrome, NB, p<0.001), and body mass index [33.2, 34.2, 35 mean body mass index (kg/m2); NB, nHB, and cHB, respectively, p<0.05]. Finally, fibrosis stage, as a marker of disease severity, was significantly correlated with the eB score (p<0.001). Conclusions: The eB score allows for a reproducible and more precise delineation of the range of ballooned hepatocyte morphology and corresponds with both clinical features of NASH and fibrosis stage.

27 January 2003 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
ARAbraham Rothman
Abraham Rothman
DLDenis J. Levy
Denis J. Levy
MSMark S. Sklansky
Mark S. Sklansky
Paul GrossfeldPaul Grossfeld
Paul Grossfeld
WAWilliam Auger
William Auger
CBCynthia A. Behling
Cynthia A. Behling

12 December 2025 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
LNLauren B. Nichols
Lauren B. Nichols
SOSebastian G. J. Oakes
Sebastian G. J. Oakes
CBCynthia Behling
Cynthia Behling
KAKathryn Harlow Adams
Kathryn Harlow Adams
MFMark H. Fishbein
Mark H. Fishbein
FCFor The Nash Crn
For The Nash Crn
Objectives: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a prevalent disease in children. Vibration‐controlled transient elastography (VCTE) offers a noninvasive alternative to liver biopsy, using controlled attenuation parameter (CAP) to estimate steatosis and liver stiffness measurement (LSM) for fibrosis. However, pediatric data with histological validation are limited. This prospective, multicenter study evaluated the accuracy of CAP and LSM in pediatric MASLD. Methods: Children with histologically confirmed MASLD from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Database 3 underwent VCTE within 6 months of liver biopsy. CAP was evaluated for correlation with steatosis grades, and LSM for correlation with fibrosis stages. The diagnostic performance of LSM in distinguishing fibrosis stages was analyzed using histological findings as the reference standard. Results: Among 92 children with MASLD (mean age 13 ± 3 years), CAP values were similar across steatosis grades (median 325, 310, and 323 dB/m for grades 1–3, respectively) and showed no significant correlation with histologic steatosis ( p = 0.422). Median LSM values increased with fibrosis stage (6.0–8.8 kPa), but significant differences were detected only between stage 0 and stage 3 fibrosis ( p = 0.037). For advanced fibrosis (stages 3–4), area under the receiver operating characteristic curve was 0.67, with sensitivity 67%, specificity 76%, positive predictive value 40%, and negative predictive value 90%. Conclusion: In this prospective, multicenter cohort, VCTE showed modest accuracy for grading steatosis or staging fibrosis in pediatric MASLD. Improved noninvasive methods are urgently needed for evaluation and monitoring in this population.

16 September 2026 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
PDF file
LNLauren B. Nichols
Lauren B. Nichols
SOSebastian G. J. Oakes
Sebastian G. J. Oakes
CBCynthia Behling
Cynthia Behling
JMJean P. Molleston
Jean P. Molleston
MMMarialena Mouzaki
Marialena Mouzaki
JSJeffrey B. Schwimmer
Jeffrey B. Schwimmer